800-845-6913
Tuteur Law Networks | Knowledge is Power.
February 20, 2008
BOSTON, Feb. 20 (MedPage Today) — Use of the blood-saving drug aprotinin (Trasylol) during coronary bypass surgery significantly increases the risk of death, according to data from two large studies.
Patients treated with aprotinin had an almost a two-fold greater mortality compared with patients given aminocaproic acid during heart surgery, Sebastian Schneeweiss, M.D., Sc.D., of Harvard, and colleagues, reported in the Feb. 21 issue of The New England Journal of Medicine.
A second study in the NEJM by a Duke-led group revealed about a 30% higher mortality risk with aprotinin versus aminocaproic acid (Amicar) or no antifibrinolytic therapy.
“Characteristics of neither the patients nor the surgeons explain the [mortality] difference, which persisted through several approaches to control confounding,” Dr. Schneeweiss and co-authors concluded.
Continue reading, ‘Aprotinin (Trasylol) Use in CABG Again Shows Extra Mortality Risk.’